GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » Net Issuance of Debt

Anebulo Pharmaceuticals (FRA:214) Net Issuance of Debt : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Anebulo Pharmaceuticals's net issuance of debt for the three months ended in Mar. 2024 was €0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Anebulo Pharmaceuticals Net Issuance of Debt Historical Data

The historical data trend for Anebulo Pharmaceuticals's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Net Issuance of Debt Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23
Net Issuance of Debt
- -0.17 - -

Anebulo Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Anebulo Pharmaceuticals Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anebulo Pharmaceuticals Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (FRA:214) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » Net Issuance of Debt
Comparable Companies
ALGS ANVS ACET ELTX HCWB IOBT KZR CRVS FIXX OCEA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ANEB:USA
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Website
https://www.anebulo.com
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines